GVAX Pancreas + cyclophosphamide

GVAX Pancreas + cyclophosphamide is a **combination immunotherapy regimen** designed for the treatment of pancreatic cancer. GVAX Pancreas is an allogeneic cancer vaccine consisting of irradiated pancreatic tumor cells engineered to secrete **granulocyte-macrophage colony-stimulating factor (GM-CSF)**, functioning as an adjuvant to stimulate a systemic, tumor-specific immune response[1][5][6]. Cyclophosphamide is a **cytotoxic alkylating agent** administered at low doses to preferentially deplete regulatory T cells (Tregs), thus overcoming immune suppression and enhancing anti-tumor responses induced by the vaccine[2][4]. This combination aims to convert the pancreatic tumor microenvironment from immunologically 'cold' (inactive) to 'hot' (active), facilitating recruitment of effector T cells and promoting cancer immunity. Multiple clinical trials (including NCT02243371, NCT03161379) have evaluated this regimen, primarily in **resectable or metastatic pancreatic adenocarcinoma**. Results have shown increased intratumoral infiltration of cytotoxic T cells, formation of tertiary lymphoid aggregates, and prolonged survival in certain subsets[1][4].

Brand names

GVAXNone for cyclophosphamide formulation

Other names

GVAX Pancreas vaccine + cyclophosphamideCy/GVAX Pancreas vaccine